We are live on ! Find out more
TMBR

Timber Pharmaceuticals, Inc.
TMBR

Delisted

TMBR was delisted on the 28th of November, 2023.

Back to rankings

13 hedge funds and large institutions have $402K invested in Timber Pharmaceuticals, Inc. in 2023 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 2 increasing their positions, 1 reducing their positions, and 3 closing their positions.

New
Increased
Maintained
Reduced
Closed

276% more capital invested

Capital invested by funds: $107K → $402K (+$295K)

100% more first-time investments, than exits

New positions opened: 6 | Existing positions closed: 3

100% more repeat investments, than reductions

Existing positions increased: 2 | Existing positions reduced: 1

18% more funds holding

Funds holding: 11 → 13 (+2)

5.9% more ownership

Funds ownership: 2.08% → 7.98% (+5.9%)

Holders
13
Holders Change
+2
Holders Change %
+18.18%
% of All Funds
0.21%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
6
Increased
2
Reduced
1
Closed
3
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$214K
2
Vanguard Group
Vanguard Group
Pennsylvania
+$64.9K
3
Renaissance Technologies
Renaissance Technologies
New York
+$40.1K
4
State Street
State Street
Massachusetts
+$32.7K
5
TSS
Two Sigma Securities
New York
+$29.6K

Top Sellers

Rank Fund Capital Flow
1
SM
Sabby Management
Florida
-$22.7K
2
Geode Capital Management
Geode Capital Management
Massachusetts
-$213
3
Morgan Stanley
Morgan Stanley
New York
-$14
4
PNC Financial Services Group
PNC Financial Services Group
Pennsylvania
-$8

TMBR Hedge Fund Activity: Q1 2023 in Review

13 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Timber Pharmaceuticals, Inc. (TMBR) for Q1 2023, worth a combined $402K — up 276% from $107K a quarter earlier.

Buyers outnumbered sellers: 6 funds opened new TMBR positions and 3 closed out — a net gain of 3 holders — while 2 added to existing stakes and 1 trimmed.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $214K. The largest seller was Sabby Management, exiting entirely with an estimated $22.7K sold.

  • 13 institutional investors held Timber Pharmaceuticals, Inc. (TMBR) as of Q1 2023, up from 11 in Q4 2022.
  • Funds reported $402K of Timber Pharmaceuticals, Inc. stock for Q1 2023, up 276% quarter-over-quarter.
  • 6 funds opened new Timber Pharmaceuticals, Inc. positions in Q1 2023 and 3 closed out, a net change of +3 holders.
  • The largest Timber Pharmaceuticals, Inc. buyer in Q1 2023 was Citadel Advisors, an estimated $214K added.
  • The largest Timber Pharmaceuticals, Inc. seller in Q1 2023 was Sabby Management, an estimated $22.7K sold.

Based on aggregated 13F filings for Q1 2023.